Clinical trials: Unfractionated Heparin
Infant, Premature, Anticoagulants
Heparin Versus no Heparin on Duration of Peripherally Inserted Central Catheter (PICC) Patency in Neonates
Background: Heparin is an anticoagulant commonly used in the neonatal population as a means to prevent catheter related occlusion and malfunction by thrombosis (clot).
- Conditions
- Infant, Premature, Anticoagulants, Thrombosis
- Trial name
- NCT00879957
- Testing
- heparin, No heparin
- Where
- United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
Chronic Obstructive Pulmonary Disease
A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD
The purpose of this study is to determine whether ODSH, when added to conventional treatment, is more effective in treating COPD exacerbations than conventional therapy alone.
- Trial name
- COPD (NCT00457951)
- Testing
- Open-Label, ODSH
- Where
- 38 sites in United States, Belgium and 3 more
- Volunteers
- 158 people
- Sponsor
- Jazz Pharmaceuticals
Myocardial Infarction
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
The primary objectives of the trial are: 1. To establish the safety and efficacy of the use of bivalirudin (+ bail-out GP IIb/IIIa inhibitors) compared to the use of unfractionated heparin + GP IIb/IIIa inhibitors in patients…
- Trial name
- NCT00433966
- Testing
- Bivalirudin, Unfractionated heparin, Bare metal stent
- Where
- United States
- Volunteers
- 3,602 people
- Sponsor
- Cardiovascular Research Foundation, New York
Venous Thromboembolic Disease, Kidney Failure, Chronic
Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data
Patients with end stage renal disease (ESRD) are at significantly increased risk of thrombosis and bleeding relative to those with normal renal function which makes anticoagulation particularly challenging.
- Trial name
- NCT04818151
- Testing
- Warfarin, Apixaban
- Where
- United States
- Volunteers
- 14,914 people
- Sponsor
- Johns Hopkins University
Hemostasis, Extracorporeal Circulation
Interchangeability of Arterial Coagulation and Venous Coagulation, in the Context of Cardiac Surgeries Under Cardiopulmonary Bypass, Using the DMDiv Hemochron Signature Elite
Adequate coagulation measured using activated clotting (ACT) is important during vascular and cardiac surgeries. Unfractionated heparin is the most common anticoagulant used.
- Conditions
- Hemostasis, Extracorporeal Circulation, Heparin, Cardio-pulmonary Bypass
- Trial name
- COAGAV (NCT05875272)
- Testing
- interchangeability of arterial or venous hemostasis
- Where
- France
- Volunteers
- 201 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Anticoagulant
Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration
Pharmacodynamic Study - Phase I Experimental Drug: Porcine sodium heparin, injectable solution - 5,000 IU/mL; Blau Farmacêutica S/A.
- Trial name
- NCT05788900
- Testing
- Heparin
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Blau Farmaceutica S.A.
Heparin-induced Thrombocytopenia Type II
Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II
The purpose of this study is to collect data on the clinical management of Argatroban in patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or without ongoing thrombosis who require parenteral…
- Trial name
- NCT00861692
- Testing
- argatroban
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Tanabe Pharma Corporation
Malignancy
Evaluation of the Effectiveness of Prophylactic LMWH by Thromboelastography
This study aims to evaluate the necessity and effectiveness of using low molecular weight heparin (LMWH) for prophylaxis in the postoperative period in patients who underwent lobectomy due to malignancy, using…
- Trial name
- NCT06484231
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people
- Sponsor
- Ege University
Open Heart Surgery
Dose for Reversal of Heparin After Cardiopulmonary Bypass
Protamine sulfate is routinely used to reverse heparin anticoagulation after cardiopulmonary bypass (CPB). The conventional dosing strategy of 1 mg protamine per 100 IU of heparin may result in excess protamine exposure, which…
- Trial name
- NCT07477977
- Testing
- Protamine sulfate
- Where
- Egypt
- Volunteers
- 195 people
- Sponsor
- Sohag University
Heart Diseases, Cardiovascular Diseases
Algorithmic Protamine Dosing for Reversal of Heparin After Cardiopulmonary Bypass
The PRODOSE trial is investigating a bespoke pharmacokinetic algorithm that calculates a tailored dose of protamine, required after cardiopulmonary bypass to reverse the action of heparin, based on individual patients and their…
- Trial name
- PRODOSE (NCT03532594)
- Testing
- PRODOSE Algorithm, Standard Care
- Where
- United Kingdom
- Volunteers
- 228 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Infertility, Low Molecular Weight Heparin
Weight Adjusted Low Molecular Weight Heparin in Recurrent Implantation Failure: a Randomized Open Labeled Trial
Prospective randomized study of patients with infertility candidates to Assisted ReproductiveTechniques (ART), screened for all inclusion and exclusion criteria, submitted to ART cycle with or without low molecular weight heparin…
- Trial name
- NCT02991950
- Testing
- Parnaparin Sodium
- Volunteers
- 271 people
- Sponsor
- Istituto Clinico Humanitas
Apheresis, Anticoagulation
Comparison of Biocompatibility of Plasmapheresis Procedures With Citrate and Heparin Anticoagulation
Membrane plasmapheresis is one of the methods for treating immune diseases. Plasmapheresis removes autoantibodies and immune complexes, paraproteins, lipoproteins and reduces the concentration of cytokines.
- Trial name
- NCT05191290
- Testing
- unfractionated heparin, Sodium Citrate
- Where
- Slovenia
- Volunteers
- 15 people
- Sponsor
- University Medical Centre Ljubljana
Heart Disease, Ischemic
Verapamil vs Heparin in Transradial Procedures
Transradial approach (TRA) for cardiac catheterization and percutaneous coronary interventions (PCI) is increasingly being used worldwide.
- Trial name
- VERMUT (NCT02454491)
- Testing
- Heparin, Verapamil
- Where
- Italy
- Volunteers
- 418 people
- Sponsor
- University Hospital of Ferrara
Acute Kidney Injury
The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy
Continuous renal replacement therapy (CRRT) has been considered as an effective modality for renal replacement therapy in hemodynamically unstable patients within intensive care unit (ICU) except for the necessity of…
- Trial name
- NCT01761994
- Testing
- Anticoagulation with nafamostat mesilate
- Where
- South Korea
- Volunteers
- 66 people
- Sponsor
- Yonsei University
Oral Anticoagulation
User Performance Evaluation of the INRatio® Prothrombin Time (PT) Monitoring System With a New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity
This multi-center study is designed to evaluate the ability of intended lay users (patients on oral anticoagulation therapy, OAT, or their caregivers) to 1) operate the INRatio Prothrombin Time (PT) Monitoring System utilizing…
- Trial name
- ECLIPSE-02 (NCT01036646)
- Where
- 4 sites in United States
- Volunteers
- 183 people
- Sponsor
- Abbott RDx Cardiometabolic
End Stage Renal Failure on Dialysis
Low Molecular Weight Heparin for Hemodialysis Anticoagulation
Low-molecular weight heparins (LMWHs) as well as Unfractionated heparin (UFH) is used as anticoagulation during hemodialysis (HD) therapy.
- Trial name
- NCT01356615
- Testing
- low molecular weight heparin (enoxaparin sodium), standard unfractionated heparin
- Volunteers
- 27 people
- Sponsor
- Tehran University of Medical Sciences
Covid19
Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units
This is a multi-center, retrospective, study to determine if therapeutic dose anticoagulation (High dose group) improves inpatient mortality in severely ill patients with COVID-19 compared to prophylactic dose anticoagulation…
- Trial name
- NCT04829552
- Where
- United States
- Volunteers
- 704 people
- Sponsor
- Corewell Health East
Inflammation
Clinical Trial on Anti-inflammatory Effect of Low-Molecular Weight Heparin in Pediatric Cataract Surgery
The purpose of this study is to determine if intraocular infusion of low-molecular weight heparin (enoxaparin) influences postoperative inflammation following pediatric cataract surgery with intraocular lens (IOL) implantation.
- Trial name
- NCT00986076
- Testing
- Enoxaparin, Balanced Salt Solution
- Where
- India
- Volunteers
- 23 people
- Sponsor
- Iladevi Cataract and IOL Research Center
Primary PCI - STEMI
STEMI Treated With Primary Angioplasty and Intravenous Lovenox or Unfractionated Heparin (UFH)
Randomized evaluation of enoxaparin (0.5mg/kg IV) versus UFH (50-70IU/kg with GPIIb/IIIa inhibitors; 70-100IU without GPIIb/IIIa inhibitors).
- Trial name
- ATOLL (NCT00718471)
- Testing
- Enoxaparin, UFH (unfractionated heparin)
- Where
- France
- Volunteers
- 910 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sepsis, Gram-Negative Bacterial Infections
Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection
Sepsis is the leading cause of death in intensive care units and a major public health concern in the world. Heparin, a widely used anticoagulant medicine to prevent or treat thrombotic disorders, has been demonstrated to prevent…
- Conditions
- Sepsis, Gram-Negative Bacterial Infections, Heparin
- Trial name
- NCT04861922
- Testing
- Unfractionated Heparin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The Third Xiangya Hospital of Central South University